Expression of FXYD6 protein in hepatocellular carcinoma and its clinical significance_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 CHEN Xiongfei , DING Lishuang , KONG Deshuai , ZHAO Xiulei , LIAO Lili , ZHANG Yaomin , LI Fengshan , LIU Ruhai

Department of General Surgery, Cangzhou Central Hospital, Cangzhou, Hebei 061001, P. R. China;

Corresponding?author：

CHEN Xiongfei, Email: chenxiongfei86@126.com

Keywords：

hepatocellular carcinoma; FXYD domain-containing ion transport regulator 6; microvascular invasion; early recurrence; prognosis

DOI：

10.7507/1007-9424.202006023

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To detect the expression of FXYD domain-containing ion transport regulator 6 (FXYD6) protein in hepatocellular carcinoma tissues and the corresponding paracancerous liver tissues, and to explore the clinical significance of FXYD6 protein expression in hepatocellular carcinoma.Methods Eighty hepatocellular carcinoma tissues and the corresponding 40 paracancerous tissues were retrospectively collected in Cangzhou Central Hospital from March 2012 to January 2018, and the expression of FXYD6 protein was examined in these tissues by strept avidin-biotin complex (SABC) immunohistochemistry. We analyzed the relationship between the expression of FXYD6 protein and clinicopathological characteristics of the patients with hepatocellular carcinoma, and the relationship between the expression of the protein and early recurrence or overall survival.Results The positive expression rate of FXYD6 protein was statistically higher in hepatocellular carcinoma tissues than that in the corresponding paracancerous tissues [77.5% (62/80) vs. 40.0% (16/40), P<0.001]. Its expression in hepatocellular carcinoma was not related with gender, age, histological differentiation, tumor maximum diameter, tumor number, AFP concentration in serum, and HBV or HCV infection (P>0.05), but with integrity of tumor capsule, microvascular invasion, and tumor stage (P<0.05). The positive FXYD6 protein expression group had a significantly higher recurrence rate than that of the negative FXYD6 protein expression group [53.2% (33/62) vs. 16.7% (3/18), P=0.006]. However, multivariate analysis results showed that high FXYD6 protein expression was not a risk factor for early relapse (P=0.422). The positive FXYD6 protein expression group had a significantly shorter postoperative survival than the negative FXYD6 expression group ( P=0.043). However, multivariate analysis results showed high FXYD6 protein expression was not a risk factor for overall survival (P=0.754).Conclusions FXYD6 protein was expressed abnormally in hepatocellular carcinoma tissues, which might be involved in the carcinogenesis and the progression of hepatocellular carcinoma. It might be a poor prognostic factor for patient with hepatocellular carcinoma.

Citation： CHEN Xiongfei, DING Lishuang, KONG Deshuai, ZHAO Xiulei, LIAO Lili, ZHANG Yaomin, LI Fengshan, LIU Ruhai. Expression of FXYD6 protein in hepatocellular carcinoma and its clinical significance. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(3): 316-321. doi: 10.7507/1007-9424.202006023 Copy

1.	Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125): 1023-1075.
2.	Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604.
3.	Tokumitsu Y, Sakamoto K, Tokuhisa Y, et al. A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy. Oncol Lett, 2018, 15(4): 4411-4422.
4.	Matsumoto T, Kubota K, Aoki T, et al. Clinical impact of anatomical liver resection for hepatocellular carcinoma with pathologically proven portal vein invasion. World J Surg, 2016, 40(2): 402-411.
5.	張小晶, 王琳. 微血管侵犯在肝癌綜合診斷與治療中的臨床意義. 中華消化外科雜志, 2019, 18(4): 336-341.
6.	Pirkmajer S, Chibalin AV. Hormonal regulation of Na⁺-K⁺-ATPase from the evolutionary perspective. Curr Top Membr, 2019, 83: 315-351.
7.	Shiina N, Yamaguchi K, Tokunaga M. RNG105 deficiency impairs the dendritic localization of mRNAs for Na⁺/K⁺ ATPase subunit isoforms and leads to the degeneration of neuronal networks. J Neurosci, 2010, 30(38): 12816-12830.
8.	Biesemann C, Gr?nborg M, Luquet E, et al. Proteomic screening of glutamatergic mouse brain synaptosomes isolated by fluorescence activated sorting. EMBO J, 2014, 33(2): 157-170.
9.	Wu M, Yuan H, Li X, et al. Identification of a five-gene signature and establishment of a prognostic nomogram to predict progression-free interval of papillary thyroid carcinoma. Front Endocrinol (Lausanne), 2019, 10: 790.
10.	Lubecka K, Flower K, Beetch M, et al. Loci-specific differences in blood DNA methylation in HBV-negative populations at risk for hepatocellular carcinoma development. Epigenetics, 2018, 13(6): 605-626.
11.	李征, 何剪太. FXYD6 蛋白在鼻咽癌組織中的表達. 中國耳鼻咽喉顱底外科雜志, 2011, 17(4): 252-254, 258.
12.	Liu J, Zhou N, Zhang X. A monoclonal antibody against human FXYD6. Hybridoma (Larchmt), 2011, 30(5): 487-490.
13.	Chen X, Sun M, Hu Y, et al. FXYD6 is a new biomarker of cholangiocarcinoma. Oncol Lett, 2014, 7(2): 393-398.
14.	陳雄飛, 周寧新, 張紅紅. FXYD6 在肝門膽管癌中的表達及臨床意義. 中國普外基礎與臨床雜志, 2016, 23(11): 1344-1347.
15.	Gao Q, Chen X, Duan H, et al. FXYD6: a novel therapeutic target toward hepatocellular carcinoma. Protein Cell, 2014, 5(7): 532-543.
16.	陳雄飛, 張執全, 袁俊建, 等. hFXYD6 真核表達載體構建及對人肝癌細胞系 SMMC7721 細胞的生物學作用的影響. 生物醫學工程與臨床, 2017, 21(6): 660-663, 671.
17.	Li ZM, Zhang HY, Wang YX, et al. MicroRNA-137 is downregulated in human osteosarcoma and regulates cell proliferation and migration through targeting FXYD6. J Drug Target, 2016, 24(2): 102-110.
18.	Xu SY, Xu PF, Gao TT. MiR-372-3p inhibits the growth and metastasis of osteosarcoma cells by targeting FXYD6. Eur Rev Med Pharmacol Sci, 2018, 22(1): 62-69.
19.	陸錄, 欽倫秀. 美國癌癥聯合委員會肝癌分期系統 (第 8 版) 更新解讀. 中國實用外科雜志, 2017, 37(2): 141-145.
20.	中華人民共和國國家衛生健康委員會醫政醫管局. 原發性肝癌診療規范 (2019 年版). 中華消化外科雜志, 2020, 19(1): 1-20.
21.	陳雄飛, 袁俊建, 張執全, 等. 抗人 FXYD6 特異性多肽單克隆功能性抗體制備及生物學作用鑒定. 重慶醫學, 2018, 47(10): 1309-1313.
22.	Croagh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol, 2014, 20(30): 10395-10404.
23.	Sayiner M, Golabi P, Younossi ZM. Disease burden of hepatocellular carcinoma: a global perspective. Dig Dis Sci, 2019, 64(4): 910-917.
24.	Zhang X, Li J, Shen F, et al. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol, 2018, 33(2): 347-354.
25.	Nitta H, Allard MA, Sebagh M, et al. Predictive model for microvascular invasion of hepatocellular carcinoma among candidates for either hepatic resection or liver transplantation. Surgery, 2019, 165(6): 1168-1175.
26.	Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol, 2019, 26(5): 1474-1493.
27.	Lu X, Pan J, Li S, et al. Establishment of a predictive genetic model for estimating chemotherapy sensitivity of colorectal cancer with synchronous liver metastasis. Cancer Biother Radiopharm, 2013, 28(7): 552-558.
28.	Shimada S, Kamiyama T, Yokoo H, et al. Clinicopathological characteristics of hepatocellular carcinoma with microscopic portal venous invasion and the role of anatomical liver resection in these cases. World J Surg, 2017, 41(8): 2087-2094.
29.	馬立峰, 郭艾, 于浩淼, 等. 鈉鉀 ATP 酶 α 亞基表達和細胞生長相關性的研究進展. 中華損傷與修復雜志 (電子版), 2013, 8(6): 68-71.
30.	王紀傳, 戴英增, 王婷婷. 表皮生長因子、雄激素受體和表皮生長因子受體在肝癌組織中的表達及影響因素分析. 癌癥進展, 2020, 18(5): 505-508.
31.	張東梅, 卿晨. 血管內皮生長因子家族及其受體與腫瘤血管新生. 醫學綜述, 2017, 23(3): 417-420, 427.

1. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, 391(10125): 1023-1075.
2. Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604.
3. Tokumitsu Y, Sakamoto K, Tokuhisa Y, et al. A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy. Oncol Lett, 2018, 15(4): 4411-4422.
4. Matsumoto T, Kubota K, Aoki T, et al. Clinical impact of anatomical liver resection for hepatocellular carcinoma with pathologically proven portal vein invasion. World J Surg, 2016, 40(2): 402-411.
5. 張小晶, 王琳. 微血管侵犯在肝癌綜合診斷與治療中的臨床意義. 中華消化外科雜志, 2019, 18(4): 336-341.
6. Pirkmajer S, Chibalin AV. Hormonal regulation of Na⁺-K⁺-ATPase from the evolutionary perspective. Curr Top Membr, 2019, 83: 315-351.
7. Shiina N, Yamaguchi K, Tokunaga M. RNG105 deficiency impairs the dendritic localization of mRNAs for Na⁺/K⁺ ATPase subunit isoforms and leads to the degeneration of neuronal networks. J Neurosci, 2010, 30(38): 12816-12830.
8. Biesemann C, Gr?nborg M, Luquet E, et al. Proteomic screening of glutamatergic mouse brain synaptosomes isolated by fluorescence activated sorting. EMBO J, 2014, 33(2): 157-170.
9. Wu M, Yuan H, Li X, et al. Identification of a five-gene signature and establishment of a prognostic nomogram to predict progression-free interval of papillary thyroid carcinoma. Front Endocrinol (Lausanne), 2019, 10: 790.
10. Lubecka K, Flower K, Beetch M, et al. Loci-specific differences in blood DNA methylation in HBV-negative populations at risk for hepatocellular carcinoma development. Epigenetics, 2018, 13(6): 605-626.
11. 李征, 何剪太. FXYD6 蛋白在鼻咽癌組織中的表達. 中國耳鼻咽喉顱底外科雜志, 2011, 17(4): 252-254, 258.
12. Liu J, Zhou N, Zhang X. A monoclonal antibody against human FXYD6. Hybridoma (Larchmt), 2011, 30(5): 487-490.
13. Chen X, Sun M, Hu Y, et al. FXYD6 is a new biomarker of cholangiocarcinoma. Oncol Lett, 2014, 7(2): 393-398.
14. 陳雄飛, 周寧新, 張紅紅. FXYD6 在肝門膽管癌中的表達及臨床意義. 中國普外基礎與臨床雜志, 2016, 23(11): 1344-1347.
15. Gao Q, Chen X, Duan H, et al. FXYD6: a novel therapeutic target toward hepatocellular carcinoma. Protein Cell, 2014, 5(7): 532-543.
16. 陳雄飛, 張執全, 袁俊建, 等. hFXYD6 真核表達載體構建及對人肝癌細胞系 SMMC7721 細胞的生物學作用的影響. 生物醫學工程與臨床, 2017, 21(6): 660-663, 671.
17. Li ZM, Zhang HY, Wang YX, et al. MicroRNA-137 is downregulated in human osteosarcoma and regulates cell proliferation and migration through targeting FXYD6. J Drug Target, 2016, 24(2): 102-110.
18. Xu SY, Xu PF, Gao TT. MiR-372-3p inhibits the growth and metastasis of osteosarcoma cells by targeting FXYD6. Eur Rev Med Pharmacol Sci, 2018, 22(1): 62-69.
19. 陸錄, 欽倫秀. 美國癌癥聯合委員會肝癌分期系統 (第 8 版) 更新解讀. 中國實用外科雜志, 2017, 37(2): 141-145.
20. 中華人民共和國國家衛生健康委員會醫政醫管局. 原發性肝癌診療規范 (2019 年版). 中華消化外科雜志, 2020, 19(1): 1-20.
21. 陳雄飛, 袁俊建, 張執全, 等. 抗人 FXYD6 特異性多肽單克隆功能性抗體制備及生物學作用鑒定. 重慶醫學, 2018, 47(10): 1309-1313.
22. Croagh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol, 2014, 20(30): 10395-10404.
23. Sayiner M, Golabi P, Younossi ZM. Disease burden of hepatocellular carcinoma: a global perspective. Dig Dis Sci, 2019, 64(4): 910-917.
24. Zhang X, Li J, Shen F, et al. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol, 2018, 33(2): 347-354.
25. Nitta H, Allard MA, Sebagh M, et al. Predictive model for microvascular invasion of hepatocellular carcinoma among candidates for either hepatic resection or liver transplantation. Surgery, 2019, 165(6): 1168-1175.
26. Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol, 2019, 26(5): 1474-1493.
27. Lu X, Pan J, Li S, et al. Establishment of a predictive genetic model for estimating chemotherapy sensitivity of colorectal cancer with synchronous liver metastasis. Cancer Biother Radiopharm, 2013, 28(7): 552-558.
28. Shimada S, Kamiyama T, Yokoo H, et al. Clinicopathological characteristics of hepatocellular carcinoma with microscopic portal venous invasion and the role of anatomical liver resection in these cases. World J Surg, 2017, 41(8): 2087-2094.
29. 馬立峰, 郭艾, 于浩淼, 等. 鈉鉀 ATP 酶 α 亞基表達和細胞生長相關性的研究進展. 中華損傷與修復雜志 (電子版), 2013, 8(6): 68-71.
30. 王紀傳, 戴英增, 王婷婷. 表皮生長因子、雄激素受體和表皮生長因子受體在肝癌組織中的表達及影響因素分析. 癌癥進展, 2020, 18(5): 505-508.
31. 張東梅, 卿晨. 血管內皮生長因子家族及其受體與腫瘤血管新生. 醫學綜述, 2017, 23(3): 417-420, 427.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expression of FXYD6 protein in hepatocellular carcinoma and its clinical significance

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content